Diadenosine polyphosphates are members of a group of dinucleoside polyphosphates that are ubiquitous, naturally occurring molecules. They form a recently identified class of compounds derived from ATP and consist of two adenosine molecules bridged by up to six phosphate groups. These compounds are stored in high concentrations in platelet dense granules and are released when platelets become activated. Some of the compounds promote platelet aggregation, while others are inhibitory. Possible roles as neurotransmitters, extracellular signalling molecules or 'alarmones' secreted by cells in response to physiologically stressful stimuli have been postulated. Recent studies suggest a role for these compounds in atrial and synaptic neurotransmission. Studies using isolated mesenteric arteries indicate an important role of phosphate chain length in determining whether diadenosine polyphosphates produce vasodilatation or vasoconstriction, but in the coronary circulation, diadenosine polyphosphates generally produce vasodilatation via mechanisms thought to involve release of NO or prostacyclin (PGI ). They produce cardiac electrophysiological effects by altering ventricular refractoriness at 2 submicromolar concentrations and reduce heart rate. Mechanisms involving K channels have been proposed in addition to the ATP involvement of P1-and P2-purinergic receptors and the specific diadenosine polyphosphate receptor identified on isolated cardiać myocytes. Clinical evidence suggests a role for diadenosine polyphosphates in hypertensive patients and those with the Chediak-Higashi syndrome. This review outlines the effects of these compounds on the cardiovascular system and considers their potential involvement in mediating the pathophysiological effects associated with platelet activation during myocardial ischaemia.
Introduction -the physiological role of diadenosine
rally occurring compounds are stored in high concenpolyphosphates trations in platelet dense granules [1] [2] [3] and are released when platelets become activated. They are also stored in Diadenosine polyphosphates are members of a group of chromaffin granules of the adrenal medulla, cholinergic dinucleoside polyphosphates that are ubiquitous, naturally synaptic vesicles, midbrain synaptosomes, the caudate occurring molecules [1] . They form a recently identified putamen and neostriatum of rats (reviewed in Ref. [4] ) and class of compounds derived from ATP and consist of two act as second messengers mediating the glucose-induced creatic b-cell [5] . Possible roles as neurotransmitters, 3 diadenosine tetraphosphate (AP A), diadenosine pentaextracellular signalling molecules or 'alarmones' secreted 4 phosphate (AP A) and diadenosine hexaphosphate (AP A) by cells in response to physiologically stressful stimuli 5 6 occur naturally, while the synthetic compound diadenosine (metabolic or oxidative stress, or heat shock) have been pyrophosphate (AP A) completes the sequence. The natupostulated [1] [2] [3] [6] [7] [8] . Recent studies suggest a role for 2 these compounds in neurotransmission [9, 10] and this has attracted much interest. AP A has been studied by some Ȭ their relation to adenosine, AMP, ADP and ATP (lower panel). Hydrolysis of ATP at the points indicated by yields ADP and orthophosphate or AMP and pyrophosphate, etc. It is thus easy to see how hydrolysis of diadenosine polyphosphates yields AMP and ADP or ATP depending on their structure (see Fig. 2 ). These metabolites may be partly responsible for the cardiovascular effects of diadenosine polyphosphates although they are known to be more resistant to hydrolysis than the nucleotides. naturally occurring compounds. Somewhat less attention outlined in [1, 13] . Briefly, the synthetic pathways of has been given to the effects of diadenosine polyphosdiadenosine polyphosphates involve the actions of aminophates on the cardiovascular system even though their acyl-tRNA synthetases [1, 7, 14, 15 ], see Fig. 2 . Synthesis of ability to alter coronary vascular resistance and cardiac diadenosine polyphosphates occurs in megakaryocytes, the electrophysiology suggests a potentially important role in progeny of which is platelets [16] . the heart [11, 12] . The aim of this review is to outline the From the perspective of the cardiovascular system, effects of diadenosine polyphosphates on the cardiovascuknowledge of their metabolism has come mainly from lar system and discuss their physiological and haematological studies which have shown that they are pathophysiological involvement in mediating the effects hydrolyzed asymmetrically, producing AMP and ADP or associated with platelet activation during myocardial is-ATP, depending on their structure [17] , see Figs. 1 and 2. chaemia.
(Hydrolysis can be symmetrical in prokaryotes [1] .) Luthje et al. [18] reported that a AP A hydrolyzing enzyme 3 (termed AP A hydrolase), present in plasma, converts The biochemical pathways involved in the synthesis and catalytic activity [19] and Zn is thought to be the normal degradation of diadenosine polyphosphates have been physiological ion while fluoride is an inhibitor [20] . Adenosine pentaphosphate (Ap ) and adenosine tetraphosphate (Ap ) are only slowly hydrolyzed (dashed line) [20] and it is not firmly established to what 5 4 extent they are metabolized further [20] (dashed line leading to a question mark). Ap can inhibit the hydrolysis of AP A and the actions of the ATPase (b) 4 4 [20] (dashed lines leading to a X to indicate enzyme inhibition). ATP and ADP also inhibit the diadenosine polyphosphate hydrolase (not indicated) [24] . ATPases which degrade ATP to ADP (b) are present on erythrocytes, leukocytes and platelets (illustrated diagrammatically) [24] . ADP can be metabolized further to AMP via adenylate kinase (c) and AMP can be converted to adenosine (ado) by 59-nucleotidase (d). Adenosine can be converted to inosine by the actions of adenosine deaminase (e) and inosine can be metabolized further to hypoxanthine via the actions of purine nucleoside phosphorylases (not indicated). Adenosine and inosine can then be taken up (solid line) via the nucleoside transporter in cardiac myocytes (panel 3) and rephosphorylated back to AMP via adenosine kinase ( f ), to ADP and to ATP [via the nucleoside diphosphate kinase ( g)]. Diadenosine polyphosphates themselves may penetrate intact cell membranes via undetermined mechanisms [26] [27] [28] [29] (dashed line labelled with a question mark traversing panels 2 and 3).
The hydrolase is regarded as a 59-nucleotide phospho-AP A and AP A is longer in whole blood than plasma [24] 3 4 diesterase and three AP Aase /AP Aase isoenzymes have while the opposite is true for ATP since the ectoenzymes 3 4 21 been identified in human serum [21] . A Mg -dependent which degrade ATP are present on erythrocytes, enzyme which is specific for AP A and does not hydrolyze leukocytes and platelets [24] .) Furthermore, in plasma, 4 AP A (termed diadenosine tetraphosphatase) has been AP A is cleaved to ATP and AMP which are then 3 4 isolated from a human leukaemic cell line [22] . metabolized further to adenosine and inosine, but in whole blood, ATP is the main product [24] . Adenosine and 2.1. Stability inosine can then be taken up via the nucleoside transporter (present in endothelial cells, erythrocytes and cardiac AP A and AP A are more stable than ATP and ADP myocytes [25] ) and rephosphorylated and converted back 3 4[ 18,23] and studies by Luthje and Ogilvie [24] have shown to ATP intracellularly [24] . This is illustrated schematicalthat ATP and ADP can affect the rate of hydrolysis of ly in Fig. 2 . AP A and AP A in blood by competitively inhibiting the 3 4 AP A hydrolase. molecules which diffuse away from the site of thrombus reported in tumour cells [27] . Delaney et al. [28] have formation without being destroyed, enabling them to act as postulated that the decrease in adenosine levels in the brain long-range signalling molecules [24] . The relative stability induced by AP A may be due to actions on adenosine 4 of AP A is also due to the fact that red blood cells, transporters mediated through P2 purinergic receptors but n platelets and leukocytes lack ectoenzymes capable of this has not been established. A recent report proposes that metabolizing AP A and AP A and that the enzymes diadenosine polyphosphates can be internalized in guinea-Previous studies using isolated mouse myocytes demonintraplatelet store of diadenosine polyphosphates from an strated that diadenosine polyphosphates were not taken up individual platelet, but under basal conditions when by cardiac myocytes [30] (discussed below), and an platelets are not activated the free concentration of explanation for this apparent discrepancy requires further diadenosine polyphosphates in the plasma is low, like that investigation.
of ADP or ATP [23] . Concentrations within platelet 6 Human erythrocytes, leukocytes and platelets have granules are of the order of 1 pmol / 10 platelets while the recently been shown to contain an intracellular AP A concentrations of ADP and ATP are 20-40-fold higher 4 hydrolase which can also hydrolyze AP A and AP A [31] . [16, 38] . The intraplatelet concentrations of diadenosine 5 6 The reasons for the presence of the hydrolase in erythropolyphosphates have been reported to vary with platelet cytes is not clear since they do not synthesize AP A and size [38] concentrations could be much higher than 1 mM and that described hydrolysis of AP A by aortic endothelial cells in the microenvironment of a platelet thrombus adherent to 3 and how the presence of ATP inhibits its hydrolysis. This a damaged vessel wall concentrations of diadenosine prolongs the life of AP A in the circulation and contributes polyphosphates could be 100 mM or higher initially. It is 3 to its ability to function as a long-range signalling moleimportant to remember that there is no experimental cule. Eventually, after ATP and ADP released from evidence to confirm this and that experimental studies platelets have been metabolized by ectoenzymes, the employing excessive extracellular concentrations of residual, intact AP A can then be hydrolyzed, acting as an diadenosine polyphosphates are consequently of question- have commented on the greater stability of diadenosine such as Salmonella typhimurium, Saccharomyces cerepolyphosphates relative to ATP and this undoubtedly visiae and Escherichia coli, intracellular concentrations of contributes to their physiological role [11, 17, [33] [34] [35] . diadenosine polyphosphates as high as 100 mM have been reported under conditions of heat shock [41] . Concentrations this high are not found in mammalian cells.
Diadenosine polyphosphates as neurotransmitters
When considering the effects of diadenosine polyphosphates it is therefore important to differentiate between A recent report by Rubino and Burnstock [9] indicates potential systemic and local effects and in view of the that diadenosine polyphosphates influence neurotransabove, local effects can be considered as occurring at mission in isolated guinea-pig atria. Sensory-motor neuroconcentrations up to 100 mM and systemic effects as transmission was evaluated as an increase in contractile occurring at concentrations from 0.1 nM up to 1 mM. tension observed following electrical stimulation and AP A, AP A, AP A, AP A and AP A at physiological [1, 4, 36] . greater than 0.1 mM which is partly due to its slow hydrolysis to ADP (which is proaggregatory) and at 5 mM it synergizes with other agonists such as platelet activating 4. Extracellular and intracellular concentrations of factor [18, 37] . AP A has inhibitory actions at 5 mM 4 diadenosine polyphosphates [18, 37] which is partly due to its slow hydrolysis to ATP which is antiaggregatory, or to a competitive antagonistic AP A and AP A are released from platelet dense effect at platelet ADP (P2T) receptors [18] . AP A and 3 4 5 granules as part of the release reaction [16, 23, 37] such that AP A have recently been identified in platelet dense 6 the concentrations of AP A and AP A in the circulating granules [42] . AP A at 100 mM is a strong inhibitor of 3 4 5 blood of an adult following platelet stimulation have been platelet aggregation to ADP producing greater inhibition estimated to be of the order of 1 mM [23] . Platelet than AP A and AP A [43] . Analogues of AP A have been approximately ten-times more potent than AP A with 4 regard to inhibition of platelet aggregation [14, 44, 45] .
Effects of diadenosine polyphosphates
6.1. Effects on smooth muscle 21 AP A and AP A at 10 mM increase cytosolic free Ca 5 6 concentrations in aortic smooth muscle [46] indicating the ability of these compounds to alter the contractile properties of muscle [42] . The effects of diadenosine polyphosphates on other types of smooth muscle have been reviewed in Ref. [4] . In isolated rabbit mesenteric arteries, Busse et al. [17] with defined receptors are indicated by bold arrows and bold type. Postulated interactions for which there is some experimental evidence are reported how removal of the endothelium was capable of indicated by dashed arrows but these may be due to hydrolysis to ATP, converting the vasodilatation seen in response to AP A 4 ADP and or adenosine, indicated by the normal arrows. Proposed
Effects on the mesenteric circulation
(1-10 mM) to vasoconstriction, while endothelial removal mechanisms for the cardiovascular effects of diadenosine polyphosphates had no effect on the vasodilator response to AP A. In to AP A suggesting the involvement of different mecha-4 nisms in producing them. Other studies using the same vascular bed have described how the presence or absence and AP A (at physiologically relevant concentrations in the 6 of endothelium influences the direction of the response to nanomolar range) produced vasoconstriction by P2X-rediadenosine polyphosphates [47] . A similar suggestion of ceptor dependent mechanisms, while the vasoconstrictive different mechanisms controlling vasodilatation in reeffects of AP A and AP A (also in the nanomolar to 2 3 sponse to AP A and AP A has been made for the coronary micromolar range) were ascribed to P1-receptor (A ) Fig. 3 . In raised tone Studies using the isolated perfused rat mesenteric arteripreparations, AP A and AP A induced vasodilatation by 2 3 al bed have reported an important role of phosphate chain P1-receptor (A ) mechanisms (Fig. 3 ), but AP A induced 2 4 length in determining whether diadenosine polyphosphates vasodilatation by P2-receptor mechanisms [51] . in the physiologically relevant nanomolar to micromolar Diadenosine polyphosphates appear to activate different range have vasodilator or vasoconstrictor actions [47] receptors in the renal circulation depending on the number mediated by P2Y-or P2X-receptors respectively (Fig. 3) of phosphate groups, but the mechanisms seem to differ due to the total negative charge presented by each molefrom those involved in the mesenteric bed [47, 51] . cule. The classification of purinoceptors is reviewed below,
In the isolated perfused rat liver, Busshardt et al.
[52] but briefly, P2X-receptors, found in vascular smooth described how AP A and AP A at 10 mM increased portal 3 4 muscle cells and which mediate vasoconstriction, are pressure, stimulated glucose output and induced a redistri- 21 1 coupled to receptor-operated ion channels with charge bution of Ca and K ions. Both AP A and AP A were 3 4 being important in mediating activation of these receptors, hydrolyzed much more slowly than ATP. In contrast to while P2Y-receptors, found in vascular smooth muscle and these observations of vasoconstriction, the response of the endothelial cells [48] are most often coupled to G-proteins coronary circulation to diadenosine polyphosphates is a [49] . Vasodilator responses, dependent on endothelial P2Y-reduction in coronary vascular resistance. receptors, can be converted to vasoconstriction if the endothelium is removed [48, 50] , but vasoconstrictor responses are endothelium-independent [48] .
7. Cardiac effects of diadenosine polyphosphates
Effects on the renal and hepatic circulations 7.1. Effects on coronary flow
The renal circulation is particularly sensitive to vasoconStudies which we and others [11, 12, 53] have undertaken strictor effects of diadenosine polyphosphates. In the have described reductions in coronary vascular resistance isolated buffer perfused rat kidney [42, 51] AP A, AP A in response to both AP A and AP A in isolated hearts.
Perfusion of isolated rabbit hearts with physiological that AP A reduced heart rate through an undetermined 4 concentrations (0.1 to 1 mM) of AP A and AP A produces mechanism and that the hypotension associated with 3 4 vasodilatation via mechanisms thought to involve direct increasing doses of AP A was not associated with a reflex of different mechanisms in the vasodilator response of the blood pressure occur and impair myocardial perfusion. heart to these two compounds. Studies using isolated
In isolated rat hearts AP A (at 5 mM) increased coronary 5 guinea-pig hearts perfused under constant flow conditions flow and left ventricular developed pressure [55] , and at 1
21
[12] indicate that AP A and AP A at concentrations of 1 to 1000 mg kg in anaesthetized rats, produced a transient 3 4 nM produce a transient vasodilatation which gradually increase in mean arterial pressure, followed by a longer recovers (Fig. 4) , but that maintained reductions in corlasting decrease in pressure [56] . Apart from these obonary perfusion pressure occur at a concentration of 1 mM.
servations, relatively little is known about the effects of These effects occur at concentrations within the physiolog-AP A and AP A on the heart. In isolated guinea-pig hearts, 5 6 ical range. Infusion of AP A into anaesthetized dogs and AP A and AP A produce coronary vasodilatation (tran- 4 5 6 pigs decreases mean arterial pressure from 20% to 80% of siently with 1 nM but maintained with 1 mM [12] ), see control depending on the concentration infused (72.5 mg phosphate (AP A) on ventricular refractoriness (1 nM, upper panel) and perfusion pressure (1 nM and 1 mM added at the points indicated by the arrows, 6 lower panel) recorded from isolated, constant flow-perfused, electrically paced guinea-pig hearts [12] . Perfusion of the hearts with all compounds increased refractory period and transiently reduced perfusion pressure at a concentration of 1 nM but during perfusion with 1 mM a sustained reduction in perfusion pressure was observed. The mechanisms responsible for these changes are currently under investigation. Data from [12] . ADP or uridine 59-triphosphate (termed P2 and subdivided Studies in electrically paced guinea-pig hearts [12] into P2X, P2Z, P2Y, P2U, P2D, P2I and P2T) [63, 65] , see indicate that AP A and AP A produce a slowly developing Fig. 3 . P2X and P2Y (principally involving ligand-gated 3 4 increase in refractory period and action potential duration ion channel receptor mechanisms and G protein-coupled at concentrations as low as 1 nM, see Fig. 4 . Electroreceptor mechanisms respectively) have been subdivided physiological effects of AP A have not been reported further [63, 65] , see Fig. 3 . AP A and AP A can interact 3 4 5 previously, but infusion of AP A into dogs and pigs with P2D receptors [65] or P receptors [10,66], see Fig. 3 . 4 4 reduces heart rate only at high concentrations (163. AP A (5 mM and 100 mg kg ) decreases heart rate in proposed provisionally [67] to describe the receptor for 5 the rat [55, 56] and AP A (at concentrations of 3 to 10 mM) diadenosine polyphosphates, but this is considered by 6 has negative chronotropic and inotropic effects in human some to be inappropriate [10] . and guinea-pig cardiac tissues [58] . AP A and AP A 5 6 increase action potential duration and refractory period at a 8.1. Evidence for a diadenosine polyphosphate receptor physiologically relevant concentration of 1 nM in isolated perfused guinea-pig hearts [12] , see Fig. 4 .
The effects of AP A have been studied in the greatest 4 Unpublished observations of Hilderman and Pivorun detail compared to those of the other diadenosine poly-(cited by Hilderman et al. [59] ) report that extracellular phosphates and a specific receptor to AP A identified on 4 addition of AP A (at a concentration not stated) to isolated the surface of isolated cardiac myocytes dissociated from 4 hearts decreases heart rate by a factor of two by a mouse hearts [30, 59] . ATP, ADP, AMP and adenosine at mechanism which has not yet been identified but has been concentrations up to 7.5 mM do not bind to this receptor postulated to involve interaction with the AP A receptor (distinguishing it from P1-and P2-receptors), but AP A, in 4 5 and transduction of the signal mediated by an ion channel addition to AP A, is a competitive agonist (K values 0.14 4 D or by activation of the phospholipase-inositol pathway or mM and 0.074 mM respectively) [30] . AP A can also bind 6 other second messenger [1] . to the receptor but the affinity of the receptor is preferen-
1
The involvement of ATP-dependent K (K ) chantial for AP A such that receptor activation enhances only ATP 4 nels in mediating the electrophysiological and vasodilatory AP A binding [68] . In the experiments of Walker et al. 4 effects of AP A in pigs has been proposed [57] since [30] AP A did not enter the myocytes by either endo- 4 4 cromakalim (a K activator) enhanced the reductions in cytosis or pinocytosis and it was concluded that localiza-ATP coronary vascular resistance observed with AP A, while tion of the receptor to the cell surface supports the 4 glibenclamide (a K inhibitor) inhibited the vasodilator suggestion that AP A is a modulator of cellular function. ATP 4 response. At the isolated myocyte level, diadenosine Although Walker et al. [30] reported an extracellular polyphosphates inhibit K channel activity when applied mechanism of action they stressed that their data do not ATP intracellularly to isolated ventricular myocytes or when eliminate the possibility of an internal receptor in cardiac cell membranes are studied in the inside-out configuration myocytes and an intracellular effect on K channels has ATP [60] . Although the concentration required for this effect is been demonstrated [29, 60] . AP A binding is specific, 4 unnaturally high (50 mM) for mammalian cells as dissaturable and reversible and can be antagonized by a cussed above, the rationale for these experiments was that monoclonal antibody raised against the receptor since diadenosine polyphosphates are synthesized intracel- [30, 69, 70] . Binding is temperature-dependent, optimal at lularly and are structurally related to ATP which gates 208C and 40% less at 378C [30] . Baxi et al. [71] reported K channels, the compounds could conceivably alter that diadenosine polyphosphates with .3 phosphate ATP channel function which they have been shown to do. groups bind to the receptor indicating that the number of phosphates between the two adenosines is important in determining the biological effects of these compounds. In 8. Receptor-mediated effects endothelial cells, binding of AP A to its receptor induces 4 activation of phospholipase C through the inositol triThe pharmacology of cardiovascular purinoceptors has phosphate pathway and is associated with the opening of 21 been reviewed extensively by Olsson and Pearson [61] and Ca channels [1] . Hoyle [3] proposed that diadenosine there is a movement towards revision of the nomenclature polyphosphates interact with receptors distinct from P1- polyphosphates stored within an individual platelet are A recent report of the synthesis of diinosine polyreleased [16, 23] , achieving concentrations in the micromophosphates, which act as antagonists for the diadenosine lar range [23] , and the net effects need to be considered. polyphosphate receptor, indicates a potentially valuable
The effects of AP A and AP A may be less important 5 6 class of compounds which can be used as pharmacological relative to those of AP A and AP A due to the different 3 4 tools with which to investigate the effects of diadenosine concentrations required for an effect. polyphosphates in more detail [72] .
Electrophysiology and arrhythmogenesis

Evidence to suggest purinoceptor involvement in the cardiovascular effects of diadenosine polyphosphates
The effects of diadenosine polyphosphates on cardiac electrophysiology are relevant physiologically as they Despite the identification of a diadenosine polyphosoccur at submicromolar concentrations [12] . Similarities to phate receptor on isolated cardiac myocytes, studies using ATP and the rapid metabolism of ATP to adenosine are intact preparations suggest that some of the cardiovascular noteworthy since the negative chronotropic and dromoteffects of diadenosine polyphosphates are mediated by ropic actions of adenosine have important clinical implicapurinoceptors. Hoyle et al. [34] reported that the negative tions in the pathogenesis of cardiovascular disease and inotropic responses of guinea-pig left atria to diadenosine treatment of arrhythmias [61] . Adenosine has cardiopropolyphosphates (10 to 100 mM) are mediated by P1-and tective effects during myocardial ischaemia (reductions in P2-receptors. In the rat, the responses to AP A were shown 5 infarct size, contractile dysfunction, microvascular injury to involve P1-receptors [56] , while the responses of and other markers of reperfusion injury) by virtue of its isolated human and guinea-pig ventricular preparations to actions on myocardial conduction, cardiac electrophysiolo-AP A appear to involve P1-receptors [58] . Studies in other 6 gy and coronary blood flow [25, [76] [77] [78] . tissues (mesenteric arteries and isolated perfused kidneys) Impaired conduction and alterations in ventricular resuggest the involvement of P1-and P2Y-receptors [47, 51] , fractoriness are important substrates for arrhythmogenesis in addition to the diadenosine polyphosphate receptor [51] .
[79] and the ability of diadenosine polyphosphates to The current status of knowledge of the involvement of increase ventricular refractoriness at nanomolar concenreceptors and other mechanisms in mediating the effects of trations [12] is important. The increases in refractoriness diadenosine polyphosphates on the cardiovascular system and action potential duration with nanomolar concentraare summarized in Table 1. tions are slowly developing (over several minutes) but are sustained unlike the transient changes in perfusion pressure observed with the same concentrations [12] . In addition 9. Similarities to the effects of ATP since the conformation of diadenosine polyphosphates changes depending on pH, their binding ability and their Diadenosine polyphosphates are structurally related to effects are likely to change during ischaemia when pH and ATP and there are strong parallels between their cardiac P are reduced [47] . Experimental studies to compare O 2 electrophysiological and haemodynamic effects where their effects during acidosis, alkalosis and alterations in known. Detailed discussion has been made elsewhere [73] .
oxygen tensions are needed to investigate this in more detail.
Platelet activation during myocardial ischaemia 10.2. Therapeutic potential of diadenosine polyphosphate It is now well established that platelet activation occurs
analogues and antagonists during myocardial ischaemia [74] and there is substantial evidence that platelet activation is a contributory arDevelopment of compounds to mimic the beneficial rhythmogenic mechanism [75] . While there is ample effects or to block the deleterious effects of diadenosine evidence for the potent effects mediated by platelet-derived polyphosphates on the cardiovascular system is potentially mediators such as eicosanoids, platelet activating factor, useful and in progress [14, 44, 45] . As part of this process, it 5-hydroxytryptamine, etc. (reviewed in Ref. [75] ) on the will be important to understand the mechanisms of action cardiovascular system, the pathophysiological role of of diadenosine polyphosphates on cardiovascular physiplatelets during myocardial ischaemia is complex and ology and pathophysiology as reviewed here. incompletely understood [74] . Release of diadenosine
The development of specific antagonists of the effects of polyphosphates from activated platelets may be involved: diadenosine polyphosphates will be difficult because of the AP A promotes platelet aggregation [18, 37] , while AP A, multiple role that these compounds have (Table 1) . Addi- elaboration and this is complicated further by the in-AP A has yet to be explored. Nonhydrolyzable analogues 6 volvement of metabolites in mediating some effects. The have the advantage of a maintained duration of action and most logical and fruitful avenue to explore is the developcould be used as adjunctive therapies. The development of ment of stable, nonhydrolyzable analogues of diadenosine selective inhibitors of diadenosine polyphosphate hydropolyphosphates with antiaggregatory effects [14, 44, 45] or lases has not yet been addressed. to achieve a similar end by the development of compounds which selectively prevent the actions of diadenosine polyphosphate hydrolases. The former is under investiga-11. Clinical relevance of diadenosine polyphosphates tion and is concentrating on stable analogues of AP A and 4 AP A (antiaggregatory) rather than AP A (proaggregatPlatelet fractions isolated from hypertensive patients 1 4 [7] Varshavsky A. Diadenosine 59,5--P ,P -tetraphosphate: A pleiotfrom normotensive subjects and this is related to the ropically acting alarmone? Cell 1983;34:711-712.
activity of AP A and AP A [42, 80] . Platelets from patients 5 6 [ normal subjects and 53% less ATP [82] . 21 Diadenosine polyphosphates evoke Ca transients in guinea-pig brain via receptors distinct from those for ATP. J Physiol 1997;504:327-335. Diadenosine polyphosphates are a newly described class [12] onary vasodilatation seen in response to some diadenosine [14] Zamecknik PC, Kim B, Gao MJ, Taylor G, Blackburn GM. 1 4 polyphosphates. More work is required to determine the Their relative importance as mediators of some of the 1 4 [15] Rapaport E, Zamecnik PC. Presence of diadenosine 59,590-P ,Pdeleterious effects associated with platelet activation durtetraphosphate (Ap A) in mammalian cells in levels varying widely 4 ing myocardial ischaemia also requires further elaboration. specific receptor antagonists which might have therapeutic
